Ledger.Open graph →
SEC Form D · Amendment · filed June 17, 2019

AsclepiX Therapeutics, Inc

Offering
$10.0M
Sold
$7.7M
Exemption
Rule 506(b)
Industry
Biotechnology
Location
BALTIMORE, MD
Type

Rule 506(b): private placement to accredited investors, no public advertising.

People & firms on this filing (21)

Steven S. Altschuler, Md · Baltimore, MDDirectorJoshua S. Barer · Baltimore, MDDirectorWendy Perrow · Baltimore, MDExec · DirectorAleksander S. Popel, Phd · Baltimore, MDDirectorJordan J. Green · Baltimore, MDDirectorKevin S. Slawin, Md · Baltimore, MDDirectorSapna S. Srivastava · Baltimore, MDDirectorArt Brown · Vancouver, British Columbia, CanadaDirectorKevin Thieneman · Hilton Head Island, SCDirectorWilliam M. Daniher · Walnut Creek, CADirectorHironobu C. Tamba · Walnut Creek, CADirectorAnkur L. Jain · New York, NYDirectorRichard C. Jelinek · Walnut Creek, CADirectorGreg Couch · Lexington, KYExec · DirectorRyan Gill · Calgary, Alberta, CanadaExec · DirectorChris Kneeland · Calgary, Alberta, CanadaDirectorBrenton K. Ahrens · Dublin, IrelandDirectorMark K. Chin · Dublin, IrelandDirectorPatrick J. Heron · Dublin, IrelandDirectorAnthony Howcroft · Irvine, CADirectorStuart Frost · Irvine, CADirector

Public SEC Form D (Reg D) filing. · View issuer on SEC EDGAR ↗